---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-203936"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:52:06.944345+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M

## Summary
- Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).
- Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.
- Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).
- FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.
- Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows.

## SEC filing metadata
- accession: 0001193125-26-203936
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/0001193125-26-203936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/bdsx-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-203936
- JSON: https://secwatch.observer/filing/0001193125-26-203936.json
- Plain text: https://secwatch.observer/filing/0001193125-26-203936.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported the first quarter ended March 31, 2026 results: revenue $25.6 million, net income Net loss of $7.8 million. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $25.6 million
  - Net income: Net loss of $7.8 million
  - Guidance: raised
  - Result: reported results
  source text: Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/0001193125-26-203936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.